1KRYS Stock Overview

A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. More details

1KRYS fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 70.1% below our estimate of its fair value

Earnings are forecast to grow 32.46% per year

Earnings grew by 116.9% over the past year

Analysts in good agreement that stock price will rise by 57.1%

Risk Analysis

Shares are highly illiquid

Profit margins (37.2%) are lower than last year (59.6%)

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Krystal Biotech, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Krystal Biotech
Historical stock prices
Current Share Price	US$114.80
52 Week High	US$0
52 Week Low	US$0
Beta	0.78
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-21.42%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	1KRYS	IT Biotechs	IT Market
7D	-7.4%	1.3%	2.3%
1Y	n/a	0.5%	15.7%

Return vs Industry: Insufficient data to determine how 1KRYS performed against the Italian Biotechs industry.

Return vs Market: Insufficient data to determine how 1KRYS performed against the Italian Market.

Price Volatility

Is 1KRYS's price volatile compared to industry and market?
1KRYS volatility
1KRYS Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.3%
Market Average Movement	5.5%
10% most volatile stocks in IT Market	8.8%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1KRYS's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1KRYS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2016	275	Krish Krishnan	www.krystalbio.com

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.

Krystal Biotech, Inc. Fundamentals Summary

How do Krystal Biotech's earnings and revenue compare to its market cap?
1KRYS fundamental statistics
Market cap	€3.39b
Earnings (TTM)	€111.18m
Revenue (TTM)	€299.07m

30.4x

P/E Ratio

11.3x

P/S Ratio

Is 1KRYS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1KRYS income statement (TTM)
Revenue	US$333.45m
Cost of Revenue	US$22.67m
Gross Profit	US$310.78m
Other Expenses	US$186.82m
Earnings	US$123.96m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	4.29
Gross Margin	93.20%
Net Profit Margin	37.18%
Debt/Equity Ratio	0%

How did 1KRYS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/19 11:12
End of Day Share Price	2025/05/16 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Krystal Biotech, Inc. is covered by 23 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Caroline Palomeque	Berenberg
Alec Stranahan	BofA Global Research
Justin Zelin	B. Riley Securities, Inc.